Featured Research

from universities, journals, and other organizations

Genetic Factor Predicts Prognosis In Brain Tumor Patients

Date:
June 27, 2007
Source:
Public Library of Science
Summary:
PLoS ONE has just published a study which defines a gene locus on chromosome 1 that predicts prognosis of brain tumor patients and may even set the basis for the development of more efficient drugs to combat brain cancer. Clinical and basic researchers from the University Hospital Basel, Switzerland, the Heinrich Heine University Düsseldorf, Germany, and the Emory University Atlanta, Ga., USA have defined the Notch2 gene as candidate gene for brain tumor development.

PLoS ONE has just published a study which defines a gene locus on chromosome 1 that predicts prognosis of brain tumor patients and may even set the basis for the development of more efficient drugs to combat brain cancer. Clinical and basic researchers from the University Hospital Basel, Switzerland, the Heinrich Heine University Düsseldorf, Germany, and the Emory University Atlanta, USA have defined the Notch2 gene as candidate gene for brain tumor development. The study was coordinated by Adrian Merlo, neurosurgeon at the University Hospital Basel.

The Notch2 locus highly predicts survival in subgroups of brain tumor patients. This gene is an important regulator of developmental processes. Taking advantage of a complex DNA duplication involving the Notch2 gene, the researchers developed a molecular assay that unambiguously distinguishes prognostically favorable brain tumor cases from cases that show rapid tumor progression.

In ongoing studies, the Basel researchers, supported by Ruth Chiquet from the Friedrich Miescher Institute, have found that Notch2 upregulates the tenascin-C gene which is well known to play a critical role in brain tumorigenesis. This new brain tumor pathway does not only offer precise diagnostic information, but also defines new targets for molecular intervention to develop drugs against this severe human disease.

Citation: Boulay J-L, Miserez AR, Zweifel C, Sivasankaran B, Kana V, et al (2007) Loss of NOTCH2 Positively Predicts Survival in Subgroups of Human Glial Brain Tumors. PLoS ONE 2(6): e576. doi:10.1371/journal.pone.0000576 (http://www.plosone.org/doi/pone.0000576)


Story Source:

The above story is based on materials provided by Public Library of Science. Note: Materials may be edited for content and length.


Cite This Page:

Public Library of Science. "Genetic Factor Predicts Prognosis In Brain Tumor Patients." ScienceDaily. ScienceDaily, 27 June 2007. <www.sciencedaily.com/releases/2007/06/070627091626.htm>.
Public Library of Science. (2007, June 27). Genetic Factor Predicts Prognosis In Brain Tumor Patients. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2007/06/070627091626.htm
Public Library of Science. "Genetic Factor Predicts Prognosis In Brain Tumor Patients." ScienceDaily. www.sciencedaily.com/releases/2007/06/070627091626.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins